The preventive role of transurethral antibiotic delivery in a rat model

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 187-194

  Ozok, Hakki U ^a   Ekim, Okan ^b   Saltas, Hakan ^a   Arikok, Ata T ^a   Babacan, Orkun ^b   Sagnak, Levent ^a   Topaloglu, Hikmet ^a   Ersoy, Hamit ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Cystitis; Fosfomycin; Infection; Prostatitis; Urinary tract

Indexed keywords

BACTERIAL DNA; FOSFOMYCIN TROMETAMOL; ANTIINFECTIVE AGENT; FOSFOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIUM IDENTIFICATION; BLADDER MUCOSA; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTITIS; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; HISTOPATHOLOGY; MALE; NONHUMAN; PROSTATE; PROSTATITIS; RAT; TISSUE CULTURE; TRANSURETHRAL DRUG ADMINISTRATION; URETHRA; URINARY TRACT INFECTION; URINE CULTURE; UROPATHOGENIC ESCHERICHIA COLI; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; MALE; RATS; RATS, WISTAR; URETHRA; URINARY TRACT INFECTIONS;

EID: 84867913714     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S32733     Document Type: Article

References (24)

1. Bootsma AM, Laguna Pes M P, Geerlings SE, Goossens A. Antibiotic prophylaxis in urologic procedures: a systematic review. Eur Urol. 2008;54(6):1270-1286.
2. Grabe M. Controversies in antibiotic prophylaxis in urology. Int J Antimicrob Agents. 2004;23 Suppl 1:S17-S23.
3. Almallah YZ, Rennie CD, Stone J, Lancashire MJ. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology. 2000;56(1):37-39.
4. Clark KR, Higgs MJ. Urinary infection following out-patient fexible cystoscopy. Br J Urol. 1990;66(5):503-505.
5. Naber KG, Hofstetter AG, Brühl P, et al; For Working group 'Urinary Tract Infections' of the Paul Erlich Societ for Chemotherapy; for Working group 'Urological Infections' of the German Society for Urology. Guidelines for the perioperative prophylaxis in urological interventions of the urinary and male genital tract. Int J Antimicrob Agents. 2001;17(4):321-326.
6. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic effcacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4):637-656.
7. Dubini F, Riviera L. Treatment of experimental cystitis in the rat with a single dose of fosfomycin trometamol. Chemioterapia. 1988;7(1):24-28.
8. Arda M. Temel Mikrobiyoloji. 2nd ed. Ankara, Turkey: Medisan Press; 2000.
9. Babacan O. Detection of virulence factors of Escherichia coli strains isolated from urogenital system infections in dogs and cats. Doctoral Thesis. Ankara University Health Science Institute. Ankara, Turkey, 2011.
10. Yamamoto S, Terai A, Yuri K, Kurazono H, Takeda Y, Yoshida O. Detection of urovirulence factors in Escherichia coli by multiplex polymerase chain reaction. FEMS Immunol Med Microbiol. 1995;12(2): 85-90.
11. Johnson JR, Stell AL. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis. 2000;181(1):261-272.
12. Bauer RJ, Zhang L, Foxman B, et al. Molecular epidemiology of 3 putative virulence genes for Escherichia coli urinary tract infection-usp, iha, and iroN (E. coli). J Infect Dis. 2002;185(10):1521-1524.
13. Hopkins WJ, Gendron-Fitzpatrick A, Balish E, Uehling DT. Time course and host responses to Escherichia coli urinary tract infection in genetically distinct mouse strains. Infect Immun. 1998;66(6): 2798-2802.
14. Nelson LK, D'Amours GH, Sproule-Willoughby KM, Morck DW, Ceri H. Pseudomonas aeruginosa las and rhl quorum-sensing systems are important for infection and infammation in a rat prostatitis model. Microbiolog y. 2009;155(Pt 8):2612-2619.
15. Afşar I, Gönül B, Şener AG, Türker M. In-vitro susceptibility of clinical isolates of escherichia coli to fosfomycin trometamol and other antibiotics. ANKEM Derg. 2005;19(2):77-79.
16. Knottnerus BJ, Nys S, Ter Riet G, Donker G, Geerlings SE, Stobberingh E. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? J Antimicrob Chemother. 2008;62(2):356-359.
17. Bergan T, Thorsteinsson SB, Albini E. Pharmacokinetic profle of fosfomycin trometamol. Chemotherapy. 1993;39(5):297-301.
18. Ishizaka K, Kobayashi S, Machida T, Yoshida K. Randomized prospective comparison of fosfomycin and cefotiam for prevention of postoperative infection following urological surgery. J Infect Chemother. 2007;13(5):324-331.
19. Shinagawa N, Mizuno I, Fukui T, et al. Prophylactic effect of fosfomycin on postoperative infection in gastroenterological surgery. Jpn J Antibiot. 2006;59(6):417-427.
20. Selvaggi F P, Battaglia M, Grossi FS, Disabato G, Cormio L. Oral prophylaxis with fosfomycin trometamol in transurethral prostatectomy and urological maneuvers: literature review and personal experience. Infection. 1992;20 Suppl 4:S321-S324.
21. Baert L, Billiet I, Vandepitte J. Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection. Infection. 1990;18 Suppl 2:S103-S106.
22. Periti P, Novelli A, Reali EF, Lamanna S, Fontana P. Prophylactic chemotherapy with fosfomycin trometamol salt during transurethral prostatic surgery: a controlled multicenter clinical trial. Eur Urol. 1987; 13 Suppl 1:S122-S131.
23. di Silverio F, Ferrone G, Carati L. Prophylactic chemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres. Results of a multicentre study. Infection. 1990;18 Suppl 2: S98-S102.
24. Leach JL, Wright CG, Edwards LB, Meyerhoff WL. Effect of topical fosfomycin on polymyxin B ototoxicity. Arch Otolaryngol Head Neck Surg. 1990;116(1):49-53.